维生素D及其受体抗肝癌作用研究进展

doi:10.3969/j.issn.1672-5069.2015.05.034

Abstract

Abstract: Hepatocellular carcinoma（HCC） is the main cause of death in patients with chronic viral hepatitis and cirrhosis，which is characterized by hidden onset，short lifetime and high mortality. It was recently identified that vitamin D，binding with its receptor，may play an important role in anti-tumor effects by inhibiting cell proliferation and inducing cell apoptosis and differentiation. This paper mainly reviewed the recent studies on mechanism of vitamin D and its receptor in inhibiting carcinogenesis，as well as the relationship between vitamin D receptor gene polymorphism and vitamin D analogue in patients with HCC，in order to provide clinical application in the treatment of HCC.

Key words: Hepatocellular carcinoma, Vitamin D, Vitamin D receptor

Li Yuling，Zhang Yin，Zhao Caiyan. Cross-talk between vitamin D and its receptors in hepatocellular carcinogenesis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 567-570.

References

[1] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide:sources，methods and major patterns in GLOBOCAN 2012. Int J Cancer，2015，136（5）:359-386.
[2] Jemal A，Bray F，Center MM，et al. Global cancer statistics. CA Cancer J Clin，2012，61（2）:69-90.
[3] Lips P. Vitamin D physiology. Prog Biophys Mol Biol，2006，92（1）:4-8.
[4] Stumpf WE，Sar M，Reid FA，et al. Target cells for 1，25-dihydroxy vitamin D3 inintestinal tract，stomach，kidney，skin， pituitary，and parathyroid. Science，1979，206（4423）:1188-1190.
[5] 池肇春．维生素D缺乏与肝疾病．临床肝胆病杂志，2009，25（5）：323-325．
[6] Grunhage F，Hochrath K，Krawczyk M，et al. Commongenetic variation in vitamin D metabolism is associated with liver tiffness. Hepatology，2012，56（5）: 1883-1891.
[7] Chiang KC，Yeh CN，Chen MF，et al. Hepatocellular carcinoma and vitamin D:A review. J Gastroenterol Hepatol，2011，26（11）:1597-1603.
[8] Wang QM，Jones JB，Studzinski GP. Cyclin-dependent kinase inhibitor p27 as amediator of the G1-S phase block induced by 1，25-dihydroxyvitamin D3 in HL60 Cells. Cancer Res，1996，56（2）:264-267.
[9] 骆文静，陈景元，徐文，等．维牛素D类似物EBl089对肝癌细胞增殖和凋亡的影响．中华预防医学杂志，2004，38（6）：415-418．
[10] Luo WJ，Chen YM，Liu MC，et al. EBl089 induces Skp2-dependent p27 accmlation leading to cell growth inhibition and cell cycle G1 phase arrest in human heptoma cells. Cancer Invest，2009，29（1）:29-37.
[11] Evans J，Ko Y，Mata W，et al. Arachidonic acid induces brain endothelial cell apoptosis via p38-MAPK and intracellular calcium signaling. Microvasc Res，2014，2862（14）:71-75.
[12] Osafi J，Hejazi A，Stutz DD，et al. Differential effects of 1，25-dihydroxy vitamin D3 on oral squamous cell carcinomas in vitro. J Diet Suppl，2014， 119（2）:145-154.
[13] 崔健，陈虹，黄秉仁，等．维生素D受体最新研究进展．生理科学进展，2011，42（2）：95-99．
[14] Seol JQ，Kim ES，Park WH，et al. Telomerase activity in acute myelogenous leukemia:clinical and biological implications. Br J Haematol，1998，100（1）:156-165.
[15] Nahon P，Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol，2012，57（3）:663-674.
[16] Zmuda JM，Cauley JA，Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev，2000，22（2）:203-217.
[17] Zhou H，Xu C，Gu M. Vitamin D receptor （VDR） gene polymorphisms and Graves' disease:a meta-analysis. Clin Endocrinol，2009，70（6）:938-945.
[18] Li L，Wu B，Yang L，et al. Association of vitamin D receptor gene polymorphisms with pancreatic cancer:A pilot study in a North China Population. Oncol Lett，2013，5（5）:1731-1735.
[19] Kame MM，Fouad SA，Salaheldin O，et al. Impact of vitamin D receptor gene polymorphisms in pathogenesis of Type-1 diabetes mellitus. Int J Clin Exp Med，2014，7（12），5505-5510.
[20] Nemenqani DM，Karam RA，Amer MG，et al. Vitamin D receptor gene polymorphisms and steroid receptor status among Saudi women with breast cancer. Gene，2015，558（2）:215-219.
[21] Sillanpaa P，Hirvonena A，Kataia V，et al. Vitamin D receptorgene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics，2004，14（4）:239-245．
[22] Deb S，Chin MY，Adomat H，et al. Ginsenoside-mediated blockade of 1α，25-dihydroxyvitamin D3 inactivation in human liver and intestine in vitro. J Steroid Biochem Mol Biol，2014，141:94-103.
[23] Baur K，Mertens JC，Schmitt J，et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor （NR 1I1） variants on fibrosis progression rate in HCV patients. Livernt，2012，32（4）:635–643.
[24] Falleti E，Bitetto D，Fabris C，et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol，2010，16（24）:3016-3024.
[25] Spina CS，Tangpricha V，Uskokovic M，et al. Vitamin D and cancer. Anticancer Res，2006，26（4A）:2515-2524.
[26] Alagbala AA，Johnson CS，Trump DL，et al. Antitumor effects of two less-calcemic vitamin D analogs （Paricalcitol and QW-1624F2-2） in squamous cell carcinoma cells. Oneology， 2006，70（6）:483-492.
[27] Akhter J，Lu Y，Finlay I，et al. 1 alpha，25-Dihydroxyvitamin D3 and its analogues，EB1089 and CB1093，profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J Surg，2001，71（7）:414-417.
[28] Dalhoff K，Dnacey J，Astrup L，et al. A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer，2003，89（2）:252-257．
[29] 盛茂林，许戈良，荚卫东，等. 维生素D类似物EBl089对肝癌细胞增殖凋亡侵袭的影响．安徽医科大学学报，2012，47（10）：1174-1177．
[30] Anakar MC，Paramasivan SK，Chattopadhyay MB，et al. 1alpha，25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J Gastroenterol，2004，10（9）:1268-1275.
[31] Singletary K，Milner J. Diet，autophagy， and cancer:a review. Cancer Epidemiol Biomarkers Prev，2008，17（7）:1596-1610.
[32] Zhang J，Zhang H，Zhang X，et al. Synergistic effect of retinoic acid and vitamin D analog EB1089-induced apoptosis of hepatocellular cancer cells. Cytotechnology，2013，65（3）:457-465.
[33] Flanagan JN，Zheng S，Chiang KC，et al. Evaluation of 19-nor-2alpha-（3-hydroxypropyl）-1alpha，25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res，2009，29（9）:3547-3553.
[34] Dan YY，Lim SG. Commentary: vitamin D deficiency and liver cancer-cause，effect or myth Aliment Pharmacol Ther，2014，39（12）:1429.
[35] Chiang KC，Persons KS，Istfan NW，et al. Fish?oil enhances the antiproliferative effect of 1alpha，25-dihydroxyvitamin D3 on liver cancer cells. Anticancer Res，2009，29（9）:3591-3596.

Cross-talk between vitamin D and its receptors in hepatocellular carcinogenesis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.